Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab study in BCG-unresponsive high-risk non-muscle-invasive bladder cancer
jRCT2080223181Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in bladder cancer and non-muscle-invasive bladder cancer (NMIBC), sponsored by Merck & Co. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2080223181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223181.